Condition: Epithelial Ovarian Cancer · Ovarian Cancer · Fallopian Tube Cancer · Sponsor: Imunon
This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.
This description comes directly from the study's public registry record.
Douglas Faller, M.D. · +1 609 896 9100 · dfaller@imunon.com
Lauren Musso · +1 609 896 9100 · lmusso@imunon.com
Always discuss trial participation with your own doctor first.
| Advent Health | Orlando, Florida, United States | Recruiting |
| Masonic Cancer Center, University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| Washington University School of Medicine in St. Louis | St Louis, Missouri, United States | Recruiting |
| Providence Cancer Institute | Portland, Oregon, United States | Recruiting |
| Sanford Health | Sioux Falls, South Dakota, United States | Recruiting |
| Erlanger Health | Chattanooga, Tennessee, United States | Recruiting |
| Providence Sacred Heart Medical Center & Children's Hospital | Spokane, Washington, United States | Recruiting |
| Froedtert and The Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06915025